155 related articles for article (PubMed ID: 27530104)
61. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.
Melling N; Rashed M; Schroeder C; Hube-Magg C; Kluth M; Lang D; Simon R; Möller-Koop C; Steurer S; Sauter G; Jacobsen F; Büscheck F; Wittmer C; Clauditz T; Krech T; Tsourlakis MC; Minner S; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Wilczak W
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146062
[TBL] [Abstract][Full Text] [Related]
62. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
[TBL] [Abstract][Full Text] [Related]
63. Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
Koide H; Kimura T; Inaba H; Sato S; Iwatani K; Yorozu T; Furusato B; Kamata Y; Miki J; Kiyota H; Takahashi H; Egawa S
Prostate; 2019 Jan; 79(1):3-8. PubMed ID: 30051483
[TBL] [Abstract][Full Text] [Related]
64. 5q21 deletion is often heterogeneous in prostate cancer.
Kluth M; Al Kilani Z; Özden C; Hussein K; Frogh S; Möller-Koop C; Burandt E; Steurer S; Büscheck F; Jacobsen F; Luebke AM; Minner S; Tsourlakis MC; Hoeflmayer D; Wittmer C; Schlomm T; Sauter G; Simon R; Wilczak W
Genes Chromosomes Cancer; 2019 Aug; 58(8):509-515. PubMed ID: 30623509
[TBL] [Abstract][Full Text] [Related]
65. Heterogenous expression of ERG oncoprotein in Malaysian men with adenocarcinoma of the prostate.
Tan JSJ; Ong KC; Ong DBL; Razack A; Lim J; Yunus R; Sundram M; Rhodes A
Malays J Pathol; 2018 Aug; 40(2):103-110. PubMed ID: 30173226
[TBL] [Abstract][Full Text] [Related]
66. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies.
Lara PN; Heilmann AM; Elvin JA; Parikh M; de Vere White R; Gandour-Edwards R; Evans CP; Pan CX; Schrock AB; Erlich R; Ross JS; Stephens PJ; McPherson J; Miller VA; Ali SM
JCO Precis Oncol; 2017; 2017():. PubMed ID: 29629426
[TBL] [Abstract][Full Text] [Related]
67. Emerging aspects of microRNA interaction with TMPRSS2-ERG and endocrine therapy.
Zoni E; Karkampouna S; Thalmann GN; Kruithof-de Julio M; Spahn M
Mol Cell Endocrinol; 2018 Feb; 462(Pt A):9-16. PubMed ID: 28189568
[TBL] [Abstract][Full Text] [Related]
68. TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens.
Yılmaz Ö; Berber U; Okçelik S; Soydan H; Ateş F; Karademir K
Turk J Urol; 2016 Jun; 42(2):60-3. PubMed ID: 27274888
[TBL] [Abstract][Full Text] [Related]
69. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis.
Ding D; Blee AM; Zhang J; Pan Y; Becker NA; Maher LJ; Jimenez R; Wang L; Huang H
Nat Commun; 2023 Aug; 14(1):4671. PubMed ID: 37537199
[TBL] [Abstract][Full Text] [Related]
70. Status of
Bhanushali A; Rao P; Raman V; Kokate P; Ambekar A; Mandva S; Bhatia S; Das BR
Prostate Int; 2018 Dec; 6(4):145-150. PubMed ID: 30505817
[TBL] [Abstract][Full Text] [Related]
71. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states.
Song H; Weinstein HNW; Allegakoen P; Wadsworth MH; Xie J; Yang H; Castro EA; Lu KL; Stohr BA; Feng FY; Carroll PR; Wang B; Cooperberg MR; Shalek AK; Huang FW
Nat Commun; 2022 Jan; 13(1):141. PubMed ID: 35013146
[TBL] [Abstract][Full Text] [Related]
72. Deletion of 3p13 is a late event linked to progression of
Kluth M; Volta H; Hussein M; Taskin B; Frogh S; Möller-Koop C; Büscheck F; Jacobsen F; Tsourlakis MC; Lübke AM; Hinsch A; Clauditz T; Graefen M; Heinzer H; Huland H; Minner S; Sauter G; Wilczak W; Schlomm T; Simon R
Cancer Manag Res; 2018; 10():5909-5917. PubMed ID: 30510458
[TBL] [Abstract][Full Text] [Related]
73. Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India.
Rawal S; Young D; Williams M; Colombo M; Krishnappa R; Petrovics G; McLeod DG; Srivastava S; Sesterhenn IA
J Cancer; 2013; 4(6):468-72. PubMed ID: 23901346
[TBL] [Abstract][Full Text] [Related]
74. Association of germline genetic variants with
Kohaar I; Li Q; Chen Y; Ravindranath L; Young D; Ali A; Sesterhenn IA; Rosner IL; Cullen J; Srivastava S; Freedman M; Petrovics G
Oncotarget; 2020 Apr; 11(15):1321-1333. PubMed ID: 32341752
[TBL] [Abstract][Full Text] [Related]
75. Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity.
Strømme JM; Johannessen B; Kidd SG; Bogaard M; Carm KT; Zhang X; Sveen A; Mathelier A; Lothe RA; Axcrona U; Axcrona K; Skotheim RI
Cancer Gene Ther; 2022 Aug; 29(8-9):1276-1284. PubMed ID: 35194199
[TBL] [Abstract][Full Text] [Related]
76. High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.
Brandi F; Grupp K; Hube-Magg C; Kluth M; Lang D; Minner S; Möller-Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wittmer C; Jacobsen F; Huland H; Steurer S; Lebok P; Hinsch A; Wilczak W; Schlomm T; Simon R
Oncol Lett; 2018 Nov; 16(5):6238-6244. PubMed ID: 30333886
[TBL] [Abstract][Full Text] [Related]
77. Gene fusions find an ERG-way to tumor inflammation.
Martin SK; Kyprianou N
Cancer Biol Ther; 2011 Feb; 11(4):418-20. PubMed ID: 21248480
[No Abstract] [Full Text] [Related]
78. Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.
Segalés L; Juanpere N; Gallarín N; Lorenzo M; López D; Perera-Bel J; Rodriguez-Vida A; Fumadó L; Cecchini L; Bellmunt J; Lloreta-Trull J; Hernández-Llodrà S
Virchows Arch; 2023 Nov; ():. PubMed ID: 38017230
[TBL] [Abstract][Full Text] [Related]
79. Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature.
Skotheim RI; Bogaard M; Carm KT; Axcrona U; Axcrona K
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189080. PubMed ID: 38272101
[TBL] [Abstract][Full Text] [Related]
80. The complexity of prostate cancer: genomic alterations and heterogeneity.
Boyd LK; Mao X; Lu YJ
Nat Rev Urol; 2012 Nov; 9(11):652-64. PubMed ID: 23132303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
